Ascites Market Size, Trends and Insights By Types (Transudative, Exudative, Others), By Diagnosis (Ultrasound, CT Scan, MRI, Blood Test, Laparoscopy, Angiography, Others), By Treatment (Medication, Paracentesis, Surgery, Others), By Route of Administration (Oral, Parenteral, Others), By End-Users (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Reports Description
The Global Ascites Market was USD 23,556 million in 2024 and is expected to reach USD 37,627 million by 2033, at a CAGR of 4.78% during the forecast period 2024 – 2033.
Ascites occur when excessive fluids build up in the abdomen or belly. The prevalence of this disease is increasing worldwide due to growing liver-related diseases. Technically, ascites are diagnosed when there is more than 25 ml of fluid in the peritoneal cavity in the abdomen. Ascites have various symptoms, such as increased abdominal size, weight gain, discomfort, and shortness of breath.
Ascites Market: Growth Factors
Growing Geriatric Population
There is a growing senior population worldwide due to the growing aging population and increasing health awareness. Ascites primarily occur in the aging population, which is more susceptible to various diseases. For instance, in the U.S., people 65 and older represented 19.2% of the population in 2023. That percentage is expected to grow to 22% by 2040.
Furthermore, the ageing population in Japan is also growing fast due to several factors, such as low birth rate, deaths outpacing births for over a decade, and increased life expectancy due to advanced healthcare expenditure.
For instance, about 28.7% of Japan’s population is 65 or older, with women forming the majority. The country is also home to a record 80,000 centenarians. A third of the population is expected to reach above 65 by 2036. Thus, such a growing geriatric population across the globe is increasing the prevalence of various chronic diseases such as cancer, heart failure, etc., which in turn propels the outburst of ascites patients.
Increasing Patients of Liver Cirrhosis
Ascites is the most common complication of liver cirrhosis. The growing of patients with liver cirrhosis due to the growing prevalence of obesity, increasing stress due to fast-paced lifestyle, growing consumption of alcohol and increasing smoking. Thus, such factors propel the prevalence of hepatitis B virus and hepatitis C virus infections, which in turn increases the outburst of ascites.
Liver cirrhosis is a significant cause of morbidity and mortality in people with chronic liver disease worldwide. In 2023, liver cirrhosis was associated with 2.7% of global deaths. High-gradient ascites are due to cirrhosis of the liver, massive liver metastases and fulminant hepatic failure. Scar tissue replaces healthy cells in liver cirrhosis, a type of liver damage.
Various factors such as the growing prevalence of hepatitis and other viruses, long-term alcohol abuse and increasing patients of non-alcoholic fatty liver disease are some of the factors propelling the ascites patients across the globe, thereby propelling the overall market growth. Furthermore, the growing prevalence of cancer patients around the world due to a sedentary lifestyle is expected to increase the of patients with ascites. Ascites caused by cancer most often occur with advanced or recurrent cancer.
Ascites Market: Restraints
High Expenditure of Ascites
The expenditure associated with Ascites is very high and increases yearly due to the growing prices of medical equipment and curative therapies used in ascites treatments. Only hospital admission and specialized care from qualified doctors and surgeons can cure ascites.
Furthermore, the cost of vaccines and medicines used to treat ascites increases exponentially due to supply chain constraints and a lack of skilled expertise. Vaccines, drugs, equipment, and kits fluctuate periodically due to growing trade war conflicts and increasing inflation worldwide.
Thus, such factors are increasing overall expenditures on ascites, which in turn hampers market expansion and growth. Less awareness about ascites treatment, the unavailability of medical infrastructure in many underdeveloped countries, and budget constraints are expected to restrain market growth during the forecast period.
Furthermore, the lack of skilled medical staff and surgeons to cure and prevent the prevalence of ascites across developing and underdeveloped countries is expected to restrain the overall market growth during the forecast period.
Ascites Market: Opportunities
Emergence of Advanced Diagnostic Technologies
Key players operating in the market are synthesising various advanced diagnostic technologies, such as Ultrasound, computerised tomography scan, and advanced magnetic resonance imaging technologies, to confirm and treat ascites. Furthermore, many stakeholders heavily invest in research and development activities to treat ascites.
For instance, some key players, such as F. Hoffmann-La Roche Ltd., AstraZeneca, GSK plc, Johnson & Johnson Private Limited, and Pfizer Inc., are using various emerging technologies, such as artificial intelligence, machine learning, computerized equipment, and predictive analytics software, to obtain real-time ultrasonography images for the detection of ascetic fluid. Machine learning and predictive analysis technologies are used to analyse and examine the history and provide important clues as to the aetiology of ascites.
Growing collaborations between key players involved in the ascites market, vaccine and diagnostic equipment developers, and end users such as hospitals, surgery centers, and clinics to develop advanced diagnostic technologies and vaccines are expected to create lucrative opportunities for the market during the forecast period.
Ascites Market: Segmentation Analysis
The global ascites market is segmented according to type, diagnosis, administration method, end user, and region. By Type, the transudate segment dominated the global market in 2023 and is expected to continue its dominance during the forecast period owing to the growing number of transudate ascites patients worldwide.
The transudate fluid is normal and spreads on the peritoneal surface. It is low in protein and is formed commonly due to an increase in portal pressure, according to the Starling hypothesis. Transudate ascites occur when patients have low protein, normal glucose, and high Ph.
Transudate ascites is the main cause of cirrhosis. Various factors such as the growing number of heart patients, increasing incidences of hypertension, a growing number of liver cirrhosis and increasing congestive heart failure patients are mainly increasing the transudate ascites patients across the globe.
Exudative ascites, which occur due to malignancy, infection, or inflammation, are expected to grow at the fastest CAGR during the forecast period. Various factors, such as the increasing prevalence of pancreatitis, peritonitis, peritoneal carcinomatosis, ischemic colitis, and intestinal obstruction disease, are mainly increasing the prevalence of exudative ascites worldwide.
By diagnosis, the Ultrasound segment dominated the global ascites market in 2023 and is expected to keep its dominance during the forecast period owing to excellent precision and accurate detection offered by ultrasound diagnosis technology.
Ultrasound technology is relatively less expensive, more precise, safer, and more reliable, and it is widely available worldwide. Various factors, such as growing technological innovations in ultrasound technology, increasing centres of ultrasound ascites detection, and growing collaboration between ultrasound companies and hospitals, are mainly driving the market growth of this segment during the forecast period.
Abdominal sonography is the most widely used technique for detecting ascites. This diagnostic method scans the abdominal area more precisely and in detail.
By end users, the hospital segment dominated the global ascites market due to growing admissions of ascites patients in hospitals due to supportive government policies.
Various factors, such as increasing investment in healthcare facilities, a growing number of hospitals worldwide, supportive government policies, growing insurance coverage and disposable income, an increasing number of patients visiting hospitals, and a growing number of government hospitals in developing countries, are mainly driving the market growth of this segment during the forecast period.
For instance, the number of hospitals in China, India, and Other emerging economies is increasing rapidly due to supportive government policies. The number of hospitals in China has increased significantly in the last five years, from roughly 26 thousand in 2019 to almost 42 thousand in 2023.
The specialty clinics segment is expected to grow at the fastest CAGR during the forecast period owing to the growing number of specialty ascites-related clinics worldwide. Increasing disposable income, a growing number of patients with ascites, and an increasing death ratio of ascites patients are some of the factors boosting the establishment of specialty clinics for ascites, thereby driving the market growth of this segment.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 23,556 Million |
| Projected Market Size in 2033 | USD 37,627 Million |
| Market Size in 2023 | USD 22,670 Million |
| CAGR Growth Rate | 4.78% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Types, Diagnosis, Treatment, Route of Administration, End-Users, Distribution Channel and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your research requirements. |
Ascites Market: Regional Analysis
The global Ascites market is segmented by region into North America, Asia Pacific, Europe, Middle East & Africa, and Latin America. Of these, the North American region held the highest market share in 2023 and is expected to keep its dominance during the forecast period owing to the growing geriatric population and increasing prevalence of liver cirrhosis in the region.
Various factors, such as the increasing prevalence of chronic disease, the increasing incidences of heart failure, the growing number of cancer patients, and increasing investment in the research and development of drugs and technologies related to ascites diagnosis, are mainly boosting the market growth of this region. Key countries such as the U.S., Canada, and Mexico are mainly boosting the market growth of this region.
For instance, according to the data published by the American College of Gastroenterology in the U.S., there are approximately 5.5 million people will be affected by liver cirrhosis in 2023. The liver cirrhosis causes 26,000 deaths each year. The number of patients is expected to increase exponentially during the forecast period owing to the growing prevalence of liver cirrhosis in adults between the ages of 25 and 64.
Asia Pacific is expected to grow at the fastest CAGR during the forecast period owing to the increasing number of patients with ascites and the growing aging population in China and Japan. Key countries such as China, India, Japan, ASEAN, South Korea, and Australia are mainly driving the market growth of this region.
Various factors, such as the rapidly expanding healthcare industry, growing disposable income, supportive government policies, growing awareness about healthcare, increasing investment in drug research and development, and innovations in diagnostic technologies of ascites, are mainly driving the market growth of this region.
China dominated the Asia Pacific ascites market and is expected to keep its dominance during the forecast period owing to supportive government policies regarding ascites research and its growing aging population. Furthermore, the growing number of liver cirrhosis patients in the country, coupled with the availability of well-established healthcare and pharmaceutical industries, are mainly driving the market growth of this region.
In the Asia Pacific region, India is expected to grow at the fastest CAGR during the forecast period owing to the growing number of government and private hospitals in the region. Various supportive policies, such as Ayushman Bharat, are providing universal healthcare coverage to all citizens of India, thereby boosting the market growth.
List of the prominent players in the Ascites Market:
- Hoffmann-La Roche Ltd.
- AstraZeneca
- GSK plc
- Johnson & Johnson Private Limited
- Lilly
- Merck & Co. Inc.
- Mylan N.V.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- WOCKHARDT
- BioVie Inc.
- Fresenius SE & Co. KGaA
- Sequana Medical NV
- BD
- Medtronic
- PharmaCyte Biotech Inc.
- GI Supply
- Others
The Ascites Market is segmented as follows:
By Types
- Transudative
- Exudative
- Others
By Diagnosis
- Ultrasound
- CT Scan
- MRI
- Blood Test
- Laparoscopy
- Angiography
- Others
By Treatment
- Medication
- Paracentesis
- Surgery
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Ascites Market, (2024 – 2033) (USD Million)
- 2.2 Global Ascites Market: snapshot
- Chapter 3. Global Ascites Market: Industry Analysis
- 3.1 Ascites Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Growing Geriatric Population
- 3.2.2 Increasing Patients of Liver Cirrhosis
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Types
- 3.7.2 Market attractiveness analysis By Diagnosis
- 3.7.3 Market attractiveness analysis By Treatment
- 3.7.4 Market attractiveness analysis By Route of Administration
- 3.7.5 Market attractiveness analysis By End-Users
- 3.7.6 Market attractiveness analysis By Distribution Channel
- Chapter 4. Global Ascites Market: Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Ascites Market: company market share, 2023
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, collaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Ascites Market: Types Analysis
- 5.1 Global Ascites Market overview: By Types
- 5.1.1 Global Ascites Market share, By Types, 2023 and 2033
- 5.2 Transudative
- 5.2.1 Global Ascites Market by Transudative, 2024 – 2033 (USD Million)
- 5.3 Exudative
- 5.3.1 Global Ascites Market by Exudative, 2024 – 2033 (USD Million)
- 5.4 Others
- 5.4.1 Global Ascites Market by Others, 2024 – 2033 (USD Million)
- 5.1 Global Ascites Market overview: By Types
- Chapter 6. Global Ascites Market – Diagnosis Analysis
- 6.1 Global Ascites Market overview: By Diagnosis
- 6.1.1 Global Ascites Market share, By Diagnosis, 2023 and 2033
- 6.2 Ultrasound
- 6.2.1 Global Ascites Market by Ultrasound, 2024 – 2033 (USD Million)
- 6.3 CT Scan
- 6.3.1 Global Ascites Market by CT Scan, 2024 – 2033 (USD Million)
- 6.4 MRI
- 6.4.1 Global Ascites Market by MRI, 2024 – 2033 (USD Million)
- 6.5 Blood Test
- 6.5.1 Global Ascites Market by Blood Test, 2024 – 2033 (USD Million)
- 6.6 Laparoscopy
- 6.6.1 Global Ascites Market by Laparoscopy, 2024 – 2033 (USD Million)
- 6.7 Angiography
- 6.7.1 Global Ascites Market by Angiography, 2024 – 2033 (USD Million)
- 6.8 Others
- 6.8.1 Global Ascites Market by Others, 2024 – 2033 (USD Million)
- 6.1 Global Ascites Market overview: By Diagnosis
- Chapter 7. Global Ascites Market: Treatment Analysis
- 7.1 Global Ascites Market overview: By Treatment
- 7.1.1 Global Ascites Market share, By Treatment, 2023 and 2033
- 7.2 Medication
- 7.2.1 Global Ascites Market by Medication, 2024 – 2033 (USD Million)
- 7.3 Paracentesis
- 7.3.1 Global Ascites Market by Paracentesis, 2024 – 2033 (USD Million)
- 7.4 Surgery
- 7.4.1 Global Ascites Market by Surgery, 2024 – 2033 (USD Million)
- 7.5 Others
- 7.5.1 Global Ascites Market by Others, 2024 – 2033 (USD Million)
- 7.1 Global Ascites Market overview: By Treatment
- Chapter 8. Global Ascites Market: Route of Administration Analysis
- 8.1 Global Ascites Market overview: By Route of Administration
- 8.1.1 Global Ascites Market Share, By Route of Administration, 2023 and 2033
- 8.2 Oral
- 8.2.1 Global Ascites Market by Oral, 2024 – 2033 (USD Million)
- 8.3 Parenteral
- 8.3.1 Global Ascites Market by Parenteral, 2024 – 2033 (USD Million)
- 8.4 Others
- 8.4.1 Global Ascites Market by Others, 2024 – 2033 (USD Million)
- 8.1 Global Ascites Market overview: By Route of Administration
- Chapter 9. Global Ascites Market: End-Users Analysis
- 9.1 Global Ascites Market overview: By End-Users
- 9.1.1 Global Ascites Market share, By End-Users, 2023 and 2033
- 9.2 Hospitals
- 9.2.1 Global Ascites Market by Hospitals, 2024 – 2033 (USD Million)
- 9.3 Homecare
- 9.3.1 Global Ascites Market by Homecare, 2024 – 2033 (USD Million)
- 9.4 Specialty Clinics
- 9.4.1 Global Ascites Market by Specialty Clinics, 2024 – 2033 (USD Million)
- 9.5 Others
- 9.5.1 Global Ascites Market by Others, 2024 – 2033 (USD Million)
- 9.1 Global Ascites Market overview: By End-Users
- Chapter 10. Global Ascites Market: Distribution Channel Analysis
- 10.1 Global Ascites Market overview: By Distribution Channel
- 10.1.1 Global Ascites Market Share, By Distribution Channel, 2023 and 2033
- 10.2 Hospital Pharmacy
- 10.2.1 Global Ascites Market by Hospital Pharmacy, 2024 – 2033 (USD Million)
- 10.3 Retail Pharmacy
- 10.3.1 Global Ascites Market by Retail Pharmacy, 2024 – 2033 (USD Million)
- 10.4 Online Pharmacies
- 10.4.1 Global Ascites Market by Online Pharmacies, 2024 – 2033 (USD Million)
- 10.5 Others
- 10.5.1 Global Ascites Market by Others, 2024 – 2033 (USD Million)
- 10.1 Global Ascites Market overview: By Distribution Channel
- Chapter 11. Ascite’s Market – Regional Analysis
- 11.1 Global Ascite’s Market Regional Overview
- 11.2 Global Ascite’s Market Share, by Region, 2023 & 2033 (USD Million)
- 11.3. North America
- 11.3.1 North America Ascite’s Market, 2024 – 2033 (USD Million)
- 11.3.1.1 North America Ascite’s Market, by Country, 2024 – 2033 (USD Million)
- 11.3.1 North America Ascite’s Market, 2024 – 2033 (USD Million)
- 11.4 North America Ascite’s Market, by Types, 2024 – 2033
- 11.4.1 North America Ascite’s Market, by Types, 2024 – 2033 (USD Million)
- 11.5 North America Ascite’s Market, by Diagnosis, 2024 – 2033
- 11.5.1 North America Ascite’s Market, by Diagnosis, 2024 – 2033 (USD Million)
- 11.6 North America Ascite’s Market, by Treatment, 2024 – 2033
- 11.6.1 North America Ascite’s Market, by Treatment, 2024 – 2033 (USD Million)
- 11.7 North America Ascite’s Market, by Route of Administration, 2024 – 2033
- 11.7.1 North America Ascite’s Market, by Route of Administration, 2024 – 2033 (USD Million)
- 11.8 North America Ascite’s Market, by End-Users, 2024 – 2033
- 11.8.1 North America Ascite’s Market, by End-Users, 2024 – 2033 (USD Million)
- 11.9 North America Ascite’s Market, by Distribution Channel, 2024 – 2033
- 11.9.1 North America Ascite’s Market, by Distribution Channel, 2024 – 2033 (USD Million)
- 11.10. Europe
- 11.10.1 Europe Ascite’s Market, 2024 – 2033 (USD Million)
- 11.10.1.1 Europe Ascite’s Market, by Country, 2024 – 2033 (USD Million)
- 11.10.1 Europe Ascite’s Market, 2024 – 2033 (USD Million)
- 11.11 Europe Ascite’s Market, by Types, 2024 – 2033
- 11.11.1 Europe Ascite’s Market, by Types, 2024 – 2033 (USD Million)
- 11.12 Europe Ascite’s Market, by Diagnosis, 2024 – 2033
- 11.12.1 Europe Ascite’s Market, by Diagnosis, 2024 – 2033 (USD Million)
- 11.13 Europe Ascite’s Market, by Treatment, 2024 – 2033
- 11.13.1 Europe Ascite’s Market, by Treatment, 2024 – 2033 (USD Million)
- 11.14 Europe Ascite’s Market, by Route of Administration, 2024 – 2033
- 11.14.1 Europe Ascite’s Market, by Route of Administration, 2024 – 2033 (USD Million)
- 11.15 Europe Ascite’s Market, by End-Users, 2024 – 2033
- 11.15.1 Europe Ascite’s Market, by End-Users, 2024 – 2033 (USD Million)
- 11.16 Europe Ascite’s Market, by Distribution Channel, 2024 – 2033
- 11.16.1 Europe Ascite’s Market, by Distribution Channel, 2024 – 2033 (USD Million)
- 11.17. Asia Pacific
- 11.17.1 Asia Pacific Ascite’s Market, 2024 – 2033 (USD Million)
- 11.17.1.1 Asia Pacific Ascite’s Market, by Country, 2024 – 2033 (USD Million)
- 11.17.1 Asia Pacific Ascite’s Market, 2024 – 2033 (USD Million)
- 11.18 Asia Pacific Ascite’s Market, by Types, 2024 – 2033
- 11.18.1 Asia Pacific Ascite’s Market, by Types, 2024 – 2033 (USD Million)
- 11.19 Asia Pacific Ascite’s Market, by Diagnosis, 2024 – 2033
- 11.19.1 Asia Pacific Ascite’s Market, by Diagnosis, 2024 – 2033 (USD Million)
- 11.20 Asia Pacific Ascite’s Market, by Treatment, 2024 – 2033
- 11.20.1 Asia Pacific Ascite’s Market, by Treatment, 2024 – 2033 (USD Million)
- 11.21 Asia Pacific Ascite’s Market, by Route of Administration, 2024 – 2033
- 11.21.1 Asia Pacific Ascite’s Market, by Route of Administration, 2024 – 2033 (USD Million)
- 11.22 Asia Pacific Ascite’s Market, by End-Users, 2024 – 2033
- 11.22.1 Asia Pacific Ascite’s Market, by End-Users, 2024 – 2033 (USD Million)
- 11.23 Asia Pacific Ascite’s Market, by Distribution Channel, 2024 – 2033
- 11.23.1 Asia Pacific Ascite’s Market, by Distribution Channel, 2024 – 2033 (USD Million)
- 11.24. Latin America
- 11.24.1 Latin America Ascite’s Market, 2024 – 2033 (USD Million)
- 11.24.1.1 Latin America Ascite’s Market, by Country, 2024 – 2033 (USD Million)
- 11.24.1 Latin America Ascite’s Market, 2024 – 2033 (USD Million)
- 11.25 Latin America Ascite’s Market, by Types, 2024 – 2033
- 11.25.1 Latin America Ascite’s Market, by Types, 2024 – 2033 (USD Million)
- 11.26 Latin America Ascite’s Market, by Diagnosis, 2024 – 2033
- 11.26.1 Latin America Ascite’s Market, by Diagnosis, 2024 – 2033 (USD Million)
- 11.27 Latin America Ascite’s Market, by Treatment, 2024 – 2033
- 11.27.1 Latin America Ascite’s Market, by Treatment, 2024 – 2033 (USD Million)
- 11.28 Latin America Ascite’s Market, by Route of Administration, 2024 – 2033
- 11.28.1 Latin America Ascite’s Market, by Route of Administration, 2024 – 2033 (USD Million)
- 11.29 Latin America Ascite’s Market, by End-Users, 2024 – 2033
- 11.29.1 Latin America Ascite’s Market, by End-Users, 2024 – 2033 (USD Million)
- 11.30 Latin America Ascite’s Market, by Distribution Channel, 2024 – 2033
- 11.30.1 Latin America Ascite’s Market, by Distribution Channel, 2024 – 2033 (USD Million)
- 11.31. The Middle-East and Africa
- 11.31.1 The Middle-East and Africa Ascite’s Market, 2024 – 2033 (USD Million)
- 11.31.1.1 The Middle-East and Africa Ascite’s Market, by Country, 2024 – 2033 (USD Million)
- 11.31.1 The Middle-East and Africa Ascite’s Market, 2024 – 2033 (USD Million)
- 11.32 The Middle-East and Africa Ascite’s Market, by Types, 2024 – 2033
- 11.32.1 The Middle-East and Africa Ascite’s Market, by Types, 2024 – 2033 (USD Million)
- 11.33 The Middle-East and Africa Ascite’s Market, by Diagnosis, 2024 – 2033
- 11.33.1 The Middle-East and Africa Ascite’s Market, by Diagnosis, 2024 – 2033 (USD Million)
- 11.34 The Middle-East and Africa Ascite’s Market, by Treatment, 2024 – 2033
- 11.34.1 The Middle-East and Africa Ascite’s Market, by Treatment, 2024 – 2033 (USD Million)
- 11.35 The Middle-East and Africa Ascite’s Market, by Route of Administration, 2024 – 2033
- 11.35.1 The Middle-East and Africa Ascite’s Market, by Route of Administration, 2024 – 2033 (USD Million)
- 11.36 The Middle-East and Africa Ascite’s Market, by End-Users, 2024 – 2033
- 11.36.1 The Middle-East and Africa Ascite’s Market, by End-Users, 2024 – 2033 (USD Million)
- 11.37 The Middle-East and Africa Ascite’s Market, by Distribution Channel, 2024 – 2033
- 11.37.1 The Middle-East and Africa Ascite’s Market, by Distribution Channel, 2024 – 2033 (USD Million)
- Chapter 12. Company Profiles
- 12.1 F. Hoffmann-La Roche Ltd.
- 12.1.1 Overview
- 12.1.2 Financials
- 12.1.3 Product Portfolio
- 12.1.4 Business Strategy
- 12.1.5 Recent Developments
- 12.2 AstraZeneca
- 12.2.1 Overview
- 12.2.2 Financials
- 12.2.3 Product Portfolio
- 12.2.4 Business Strategy
- 12.2.5 Recent Developments
- 12.3 GSK plc
- 12.3.1 Overview
- 12.3.2 Financials
- 12.3.3 Product Portfolio
- 12.3.4 Business Strategy
- 12.3.5 Recent Developments
- 12.4 Johnson & Johnson Private Limited
- 12.4.1 Overview
- 12.4.2 Financials
- 12.4.3 Product Portfolio
- 12.4.4 Business Strategy
- 12.4.5 Recent Developments
- 12.5 Lilly
- 12.5.1 Overview
- 12.5.2 Financials
- 12.5.3 Product Portfolio
- 12.5.4 Business Strategy
- 12.5.5 Recent Developments
- 12.6 Merck & Co. Inc.
- 12.6.1 Overview
- 12.6.2 Financials
- 12.6.3 Product Portfolio
- 12.6.4 Business Strategy
- 12.6.5 Recent Developments
- 12.7 Mylan N.V.
- 12.7.1 Overview
- 12.7.2 Financials
- 12.7.3 Product Portfolio
- 12.7.4 Business Strategy
- 12.7.5 Recent Developments
- 12.8 Novartis AG
- 12.8.1 Overview
- 12.8.2 Financials
- 12.8.3 Product Portfolio
- 12.8.4 Business Strategy
- 12.8.5 Recent Developments
- 12.9 Pfizer Inc.
- 12.9.1 Overview
- 12.9.2 Financials
- 12.9.3 Product Portfolio
- 12.9.4 Business Strategy
- 12.9.5 Recent Developments
- 12.10 Sanofi
- 12.10.1 Overview
- 12.10.2 Financials
- 12.10.3 Product Portfolio
- 12.10.4 Business Strategy
- 12.10.5 Recent Developments
- 12.11 Sun Pharmaceutical Industries Ltd.
- 12.11.1 Overview
- 12.11.2 Financials
- 12.11.3 Product Portfolio
- 12.11.4 Business Strategy
- 12.11.5 Recent Developments
- 12.12 Teva Pharmaceutical Industries Ltd.
- 12.12.1 Overview
- 12.12.2 Financials
- 12.12.3 Product Portfolio
- 12.12.4 Business Strategy
- 12.12.5 Recent Developments
- 12.13 WOCKHARDT
- 12.13.1 Overview
- 12.13.2 Financials
- 12.13.3 Product Portfolio
- 12.13.4 Business Strategy
- 12.13.5 Recent Developments
- 12.14 BioVie Inc.
- 12.14.1 Overview
- 12.14.2 Financials
- 12.14.3 Product Portfolio
- 12.14.4 Business Strategy
- 12.14.5 Recent Developments
- 12.15 Fresenius SE & Co. KGaA
- 12.15.1 Overview
- 12.15.2 Financials
- 12.15.3 Product Portfolio
- 12.15.4 Business Strategy
- 12.15.5 Recent Developments
- 12.16 Sequana Medical NV
- 12.16.1 Overview
- 12.16.2 Financials
- 12.16.3 Product Portfolio
- 12.16.4 Business Strategy
- 12.16.5 Recent Developments
- 12.17 BD
- 12.17.1 Overview
- 12.17.2 Financials
- 12.17.3 Product Portfolio
- 12.17.4 Business Strategy
- 12.17.5 Recent Developments
- 12.18 Medtronic
- 12.18.1 Overview
- 12.18.2 Financials
- 12.18.3 Product Portfolio
- 12.18.4 Business Strategy
- 12.18.5 Recent Developments
- 12.19 PharmaCyte Biotech Inc.
- 12.19.1 Overview
- 12.19.2 Financials
- 12.19.3 Product Portfolio
- 12.19.4 Business Strategy
- 12.19.5 Recent Developments
- 12.20 GI Supply
- 12.20.1 Overview
- 12.20.2 Financials
- 12.20.3 Product Portfolio
- 12.20.4 Business Strategy
- 12.20.5 Recent Developments
- 12.21 Other.
- 12.21.1 Overview
- 12.21.2 Financials
- 12.21.3 Product Portfolio
- 12.21.4 Business Strategy
- 12.21.5 Recent Developments
- 12.1 F. Hoffmann-La Roche Ltd.
List Of Figures
Figures No 1 to 47
List Of Tables
Tables No 1 to 152
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2033
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- Hoffmann-La Roche Ltd.
- AstraZeneca
- GSK plc
- Johnson & Johnson Private Limited
- Lilly
- Merck & Co. Inc.
- Mylan N.V.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- WOCKHARDT
- BioVie Inc.
- Fresenius SE & Co. KGaA
- Sequana Medical NV
- BD
- Medtronic
- PharmaCyte Biotech Inc.
- GI Supply
- Others
FAQs
The increasing patients number of liver cirrhosis and with increasing investment in the hospitals and surgical centers are major drivers in global Ascites market.
The “Transudative” category dominated the market in 2023.
The key players in the market are F. Hoffmann-La Roche Ltd., AstraZeneca, GSK plc, Johnson & Johnson Private Limited, Lilly, Merck & Co. Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., WOCKHARDT, BioVie Inc., Fresenius SE & Co. KGaA, Sequana Medical NV, BD, Medtronic, PharmaCyte Biotech Inc., GI Supply, Other.
“North America” had the largest share in the Ascites Market.
The global market is projected to grow at a CAGR of 4.78% during the forecast period, 2024-2033.
The Ascites Market size was valued at USD 23,556 Million in 2024.